Avalo Therapeutics (AVTX) Non-Current Debt (2014 - 2023)

Avalo Therapeutics (AVTX) has 8 years of Non-Current Debt data on file, last reported at $10.5 million in Q1 2023.

• For the quarter ending Q1 2023, Non-Current Debt changed N/A year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2023 stood at $10.5 million (changed N/A YoY), and the FY2022 full-year result was $13.5 million, down 58.93% from the prior year.
• Non-Current Debt for Q1 2023 stood at $10.5 million, down from $13.5 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $32.8 million in Q4 2021 and bottomed at $10.5 million in Q1 2023.
• The 4-year median for Non-Current Debt is $14.3 million (2019), against an average of $16.9 million.
• The widest annual swing landed in 2019, when Non-Current Debt declined 0.68%; it then sank 58.93% in 2022.
• A 4-year view of Non-Current Debt shows it stood at $14.3 million in 2019, then jumped by 130.33% to $32.8 million in 2021, then plunged by 58.93% to $13.5 million in 2022, then slipped by 22.36% to $10.5 million in 2023.
• The last three Non-Current Debt figures came in at $10.5 million (Q1 2023), $13.5 million (Q4 2022), and $16.5 million (Q3 2022), per Business Quant data.

Peer Comparison